ReviewMedicine2025
Insights into the mechanisms of apoptosis and pathogenesis in enterovirus 71 infections: A review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study examines the intricate interactions between enterovirus 71 (EV71) and various programmed cell death pathways, specifically apoptosis, necroptosis, and pyroptosis, which collectively shape the pathogenesis and severity of EV71 infections. Primarily affecting children under 5 years of age, EV71 is a leading cause of hand, foot, and mouth disease and has been linked to severe neurological and systemic complications. This paper highlights how EV71 leverages distinct cell death mechanisms to enhance viral replication and amplify disease pathology. Apoptosis, for example, may restrict viral dissemination by systematically eliminating infected cells; however, EV71's activation of necroptosis and pyroptosis induces robust inflammatory responses, potentially resulting in extensive tissue damage and adverse health outcomes. Additionally, this study also summarizes recent advancements in the field, with an emphasis on experimental studies and clinical trials focused on vaccine and antiviral therapy development. Despite substantial progress, challenges persist, notably in achieving reliable vaccine efficacy and formulating safe treatment options specifically for pediatric populations. Moving forward, the review suggests that future research should delve further into understanding EV71-related complications, developing broad-spectrum antiviral agents, and investigating host genetic factors that may influence disease progression and outcomes. Ultimately, this research is essential for the development of targeted interventions capable of reducing severe symptoms without compromising the immune response, underscoring the importance of these efforts for public health and the management of infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.